Drug Profile
Amlodipine/rosuvastatin/valsartan - HK inno.N
Alternative Names: CJ-30060Latest Information Update: 14 Oct 2021
Price :
$50
*
At a glance
- Originator CJ HealthCare
- Developer HK inno.N
- Class Antihyperlipidaemics; Antihypertensives; Branched-chain amino acids; Dihydropyridines; Fluorobenzenes; Ischaemic heart disorder therapies; Pyrimidines; Small molecules; Sulfonamides; Tetrazoles
- Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Hyperlipidaemia; Hypertension
Highest Development Phases
- No development reported Hyperlipidaemia; Hypertension
Most Recent Events
- 14 Oct 2021 No development reported - Phase-III for Hyperlipidaemia in South Korea (PO)
- 14 Oct 2021 No development reported - Phase-III for Hypertension in South Korea (PO)
- 18 Jun 2020 CJ HealthCare is now called HK inno.N